Currently, we have no statistically significant data to pinpoint whether MEN2-CLA should be approached differently than non-MTC cases and whether LCA in association with a thyroid malignancy/neuroendocrine neoplasm is more severe apart from an increased disease burden that comes with the clinical expression due to the RET pathogenic variants. This evidence concerns the gene SELPLG and Leber congenital amaurosis.